Financial Data and Key Metrics Changes - The company reported a GAAP net loss of $123 million or $1.55 per share for Q3 2026, primarily due to the change in fair value of StepStone Private Wealth profits interests [4] - Fee-related earnings were $89 million, up 20% year-over-year, with a FRE margin of 37% [5][17] - Adjusted net income for the quarter was $80 million or $0.65 per share, an increase from $53 million or $0.44 per share in the same quarter last year [5][20] Business Line Data and Key Metrics Changes - Core fee-related earnings, excluding retroactive fees, were $88 million, reflecting a 35% increase compared to the prior year [5] - The company generated gross AUM additions of over $8 billion in the quarter and over $34 billion for the calendar year, marking its best fundraising period [7][13] - In private wealth, the platform grew to $15 billion with over $2.2 billion in new subscriptions for the quarter [8][15] Market Data and Key Metrics Changes - Approximately two-thirds of the inflows were from outside North America, with strong fundraising in Asia and Europe [13][60] - The company reported a retention rate on managed accounts of over 90%, with reups growing by nearly 30% [14] Company Strategy and Development Direction - The company is focused on diversifying its investment approach across various asset classes and capital structures, particularly in the context of AI evolution [10][11] - The firm is currently in the market with several funds, including private equity co-investment and secondaries funds, expecting to activate fee-earning capital in the coming year [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the earnings trajectory, citing an improving capital market environment that may yield stronger realizations [6] - The company anticipates continued growth in private wealth subscriptions and is optimistic about the upcoming fundraising efforts [8][9] Other Important Information - The company plans to pay out a supplemental dividend at the end of the fiscal year, subject to board approval based on performance-related revenues [20] - The net accrued carry finished the quarter at $875 million, indicating a mature investment portfolio ready for harvesting [21] Q&A Session Summary Question: Exposure to software companies across the portfolio - Management highlighted the diversified approach to private markets investing, emphasizing that not all software companies are equal and that they focus on portfolio construction and diversification to manage risks [24][25] Question: Growth in private wealth business and scaling existing products - Management noted that they are in early stages of building syndicates for new funds and expect to see growth in distribution over the coming year, with no new product announcements planned [31] Question: Managing inflows for Spring fund - Management stated that they have not faced issues with inflows and continue to see strong opportunities for deployment across various avenues [35] Question: Expectations for next vintages of funds - Management tempered expectations for modest growth in fund sizes, emphasizing the importance of matching fundraising to the size of the opportunity [37] Question: Performance attribution for Spring fund - Management explained that the performance was driven more by direct secondaries rather than discounts, highlighting the proactive approach in identifying value drivers [44][46]

Financial Data and Key Metrics Changes - The company reported revenues of $303,000 for the quarter, representing a 51% increase compared to the same quarter last year [8] - For the first half of the fiscal year, revenues increased by 85% to over $600,000, marking the best first half ever for the company [5][8] - Gross profit totaled $220,000, or 72.6% of revenues, which was a 23% increase from $180,000, or 89.5% of revenues in the same quarter a year ago [9] - Net loss totaled $3 million, or $0.11 per share, compared to a net loss of $2.2 million in the same quarter last year [10] - Available cash increased to $768,000 from $220,000 at the end of the previous fiscal year [11] Business Line Data and Key Metrics Changes - The U.S. distributor network increased sales by 35% year-over-year, contributing $237,000, or 75% of total revenues for the quarter [4][8] - The new product, Precise PRP, generated increased revenue during the quarter, with 42% of revenue attributed to PRP and 58% to Spring [34] Market Data and Key Metrics Changes - The veterinary healthcare market in Mexico is projected to grow at a CAGR of 11%, reaching approximately $2.4 billion in six years [3] - The European animal market is estimated at over $16.56 billion and is projected to grow at a CAGR of 8.6% [3] - The U.K. market exceeds $2.6 billion and is growing at a 7.8% CAGR [4] Company Strategy and Development Direction - The company aims to expand the use of its flagship product, Spring, and increase awareness of Precise PRP for treating osteoarthritis in animals [13] - The company is exploring the introduction of products to human markets and has formed partnerships to enhance its market presence [7][18] - A strategic collaboration with Digital Landia aims to integrate AI technology into the company's platform, enhancing diagnostic capabilities [21][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued strong sales momentum and market penetration for the remainder of fiscal 2026 [27] - The company anticipates another year of record growth and improving bottom line as it expands the use of Spring and Precise PRP [27] - The third and fourth quarters are expected to be particularly strong due to increased industry events driving product awareness [28] Other Important Information - The company qualified to begin trading on the OTCQX best market, enhancing visibility and liquidity for investors [12] - The appointment of Josh Rubin to the board of directors is expected to provide valuable insights into growth-stage companies [6] Q&A Session Summary Question: How many clinics are heavy users of the product? - The learning curve for veterinarians to adopt the product ranges from six months to a year, with anecdotal evidence showing continued growth in adoption [32] Question: Can you break down the revenue between Spring and PRP? - Approximately 42% of revenue was from PRP and 58% from Spring, with the PRP revenue only reflecting the canine version as equine shipments just began [34][35] Question: Do you have any corporate clinics that have adopted your product corporate-wide? - No corporate-wide adoption has occurred yet, as each corporate clinic allows veterinarians to make their own decisions [37] Question: Can you provide a breakdown between companion versus equine revenue? - The company tracks these markets separately and plans to provide more detailed segment reporting in the future [39]

Core Insights - Katrin Adt has been appointed as the new CEO of the Dacia brand, succeeding Denis Le Vot, effective September 1, 2025 [2][3] - Adt brings nearly 26 years of experience in the automotive industry, having held various senior positions at Daimler and Mercedes-Benz, including CEO of Mercedes-Benz in Luxembourg and CEO of the Smart brand [6] - The Dacia brand is recognized for its affordable mobility solutions and is currently expanding with the launch of its new C-segment SUV, BIGSTER [5][12] Company Leadership - François Provost, CEO of Renault Group, expressed gratitude to Denis Le Vot for his contributions and welcomed Katrin Adt, highlighting her experience as a key asset for Dacia [3] - Fabrice Cambolive, Chief Growth Officer of Renault Group, emphasized Adt's expertise in business development and the importance of electrifying Dacia's product range [4] Brand Positioning and Strategy - Dacia is positioned as a specialist brand for affordable mobility, aiming to establish itself as a benchmark in electrified vehicles [4][12] - The brand has seen significant success, with models like Sandero and Duster becoming best-sellers in their respective categories in Europe [12] - Adt aims to continue Dacia's momentum and address the challenges of electrification while maintaining the brand's commitment to accessible mobility [7]

Financial Data and Key Metrics Changes - The company reported revenues of $298,000, representing a 141% increase compared to the same quarter last year [6][4] - Gross profit totaled $187,000, which is 63% of revenues, marking a 69% increase from $111,000 in the same quarter last year [7] - Operating loss decreased by 10% to $1,800,000 compared to the same quarter a year ago [8] - Net loss available to common stockholders was $2,300,000, or a negative loss of $0.09 per share, which is a 15% improvement from the previous year's net loss of $2,000,000 [8] - Available cash increased to $3,300,000 from $220,000 as of March 31, 2025 [9] - Total liabilities decreased by 39% to $1,200,000 during the quarter [9] Business Line Data and Key Metrics Changes - The U.S. National distributor network increased sales by 192% year-over-year, contributing $198,000 or 67% of total revenue [4][6] - The introduction of the new Precise PRP product alongside Spring contributed to the revenue increase [6] Market Data and Key Metrics Changes - The Mexican veterinary health care market is projected to grow at a compounded annual growth rate of 11%, reaching $2.4 billion by February 2031 [3] - The U.S. animal health market is expected to double to $11.3 billion by February 2030, providing significant growth opportunities [24] Company Strategy and Development Direction - The company is focused on expanding the adoption of its flagship product, Spring, and increasing awareness of Precise PRP for treating osteoarthritis in animals [12] - Strategic partnerships have been formed, including collaborations with Commonwealth Markets and Piezo BioMembrane, to enhance product offerings and market reach [20][22] - The company is integrating AI technology with its veterinary products to create a global pet care ecosystem [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued strong sales momentum and market penetration for fiscal 2026 and beyond [24] - The company believes it is well-positioned to accelerate growth and expand into high-growth markets [24] Other Important Information - The company has recently qualified to trade on the OTCQX best market, enhancing visibility and liquidity for investors [11] - The commercialization of Spring and Precise PRP has received favorable feedback from veterinarians regarding their effectiveness [14] Q&A Session Summary - No questions were raised during the Q&A session, leading to the conclusion of the call [29][33]

Financial Data and Key Metrics Changes - PetVivo reported a revenue growth of 17% for fiscal year 2025, totaling a record $1,100,000, driven largely by an expanding nationwide distributor network [4][8] - Gross profit was $995,000, representing 87.8% of revenues, which is a decrease from 89.5% in fiscal year 2024 [9] - Operating expenses decreased by 21% to $9,100,000, primarily due to a strategic cost reduction and restructuring program [9] - Net loss improved by 27% to $8,000,000 or $0.39 per share, compared to a net loss of $11,000,000 or $0.78 per share in fiscal year 2024 [10] Business Line Data and Key Metrics Changes - The expanding distributor network contributed $958,000 in sales, accounting for 86% of total revenues [4][8] - The company is focusing on increasing its market share in the companion animal market while maintaining growth in the equine market [4][5] Market Data and Key Metrics Changes - The veterinary healthcare market in Mexico is projected to grow at a 6% CAGR, reaching nearly $2,000,000,000 by 2026 [3] - The U.S. animal health market is projected to double to $11,300,000,000 by 2030, providing significant growth opportunities [19] Company Strategy and Development Direction - The company aims to drive greater adoption of its products, particularly Spring and Precise PRP, by increasing awareness among key decision-makers [12] - Strategic partnerships and collaborations, such as with Digital Landia, are expected to enhance product visibility and market penetration [17][24] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's position to accelerate growth and expand into high-growth markets [19] - The company anticipates strong sales momentum and market penetration in fiscal year 2026, supported by recent advancements and partnerships [18] Other Important Information - The company has strengthened its leadership team and commercial operations, appointing experienced executives to key positions [21][22] - A successful offering of $5,000,000 in Series B convertible preferred stock was completed to support growth strategies [11] Q&A Session Summary Question: How much dilution do you expect from the conversion of the Series B preferred? - The conversion is on a one-to-one basis, with an additional 5,000,000 shares expected if fully converted [28][30] Question: What is the average price per vial of the Spring injection that veterinarians are charging for canines? - The average charge is around $800 per joint, varying between $500 to $1,200 depending on the complexity of the problem [33][35] Question: Can you talk a little bit about the human trials and their projected path? - The company is excited about the results from small and large animal studies, with potential applications in the human market for osteoarthritis, which is valued at approximately $11,200,000,000 in the U.S. [43][44]

Summary of StepStone Group Conference Call Company Overview - **Company**: StepStone Group - **Industry**: Private Markets Investment and Advisory - **Assets Under Management**: Approximately $190 billion, overseeing nearly $500 billion in private market allocations [3][4] Key Points and Arguments Business Model and Market Position - StepStone operates as a solution provider, differentiating itself from traditional General Partners (GPs) like Blackstone and KKR by allocating capital on behalf of clients to funds managed by GPs while also managing direct strategies [4][5] - The private markets have grown from approximately $2 trillion in assets under management (AUM) in 2007 to over $15 trillion today, indicating a significant market opportunity for solution providers [7][8] - StepStone's strategies include primary fund investments, co-investments, and secondary interests across four asset classes: private equity, venture capital, real estate, and private credit [6] Fundraising Success - Fiscal year 2025 was a record year for StepStone with total inflows of $30 billion, including $20 billion from separate accounts and $10 billion from commingled funds [10][11] - The company achieved a 90% re-up rate for managed accounts, with clients increasing their investments by an average of 30% upon re-upping [14][15] - The commingled fund side saw significant success, with over $3 billion raised across three different funds, marking the largest fundraising year for commingled funds since inception [12][13] Global Footprint and Client Base - Over 60% of StepStone's business comes from outside the U.S., allowing the firm to tap into growing allocations in emerging markets [11][24] - The firm aims to work with a diverse range of clients, from large sovereign wealth funds to individual investors, reflecting a solutions-oriented approach [9] Partnership with FTSE Russell - StepStone announced a partnership with FTSE Russell to develop private asset indices and analytics products, aiming to address the challenge of measuring performance across liquid and illiquid assets [17][20] - The partnership will initially focus on benchmarking solutions, with potential for investable products like index funds in the future [18][19] Macro Environment and Market Dynamics - The macroeconomic environment has been volatile, impacting fundraising and investment activity; however, StepStone's diversification across asset classes and geographies has mitigated some risks [22][24] - The secondary market has seen significant growth, with total secondary volume reaching approximately $160 billion in 2024, more than doubling in the last five to six years [33][34] Opportunities in Private Wealth and Institutional Markets - Private wealth management has seen substantial growth, with assets on the platform exceeding $8 billion, driven by a strong performance and efficient capital structures [40][42] - There is a growing interest in private credit and infrastructure as newer asset classes, with many institutional investors beginning to allocate to these areas [30][29] Future Outlook - StepStone is focused on expanding its international operations and product offerings, particularly in the private wealth channel and retirement markets [48][54] - The firm is exploring opportunities in public-private partnerships and the retirement channel, recognizing the potential for significant asset growth in these areas [50][53] Additional Important Insights - The firm has developed a comprehensive product suite for private wealth, catering to a wide range of investors and emphasizing a solutions-oriented approach [44][45] - The secondary market is expected to continue growing, driven by liquidity challenges faced by limited partners (LPs) and the increasing importance of secondary transactions [31][33] This summary encapsulates the key insights and developments discussed during the conference call, highlighting StepStone Group's strategic positioning, fundraising success, and future opportunities in the private markets landscape.